Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611408 | 0.92 | MRGPRX1 (0.52) | MRGPRX1MAP4K4F10MAPTALDH1A1 | |
| SCHEMBL6584777 | 0.81 | MRGPRX1 (0.53) | MRGPRX1MAP4K4F10MAPTALDH1A1 | |
| SCHEMBL252692 | 0.79 | TRPA1 (0.58) | MRGPRX1MAP4K4ALDH1A1TRPA1EGFR | |
| Hydrochloric Acid SCHEMBL21611617 | 0.77 | ALK (0.40) | MRGPRX1MAP4K4F10MAPTALDH1A1 | |
| SCHEMBL21611480 | 0.77 | SMN1; SMN2 (0.56) | MAP4K4MAPTALDH1A1KDM4EFLT3 | |
| SCHEMBL6289347 | 0.75 | ALDH1A1 (0.54) | F10MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL6290496 | 0.75 | ALDH1A1 (0.54) | F10MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL21611491 | 0.75 | EPAS1 (0.43) | MRGPRX1MAPTALDH1A1TRPA1LMNA | |
| SCHEMBL2455031 | 0.74 | RET (0.63) | — | |
| SCHEMBL7938427 | 0.74 | MAPT (0.46) | MAP4K4MAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197902-A1 | Use of Pyrimidine Compounds in the Preparation of Parasiticides | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20070155757-A1 | Use of pyrimidine compounds in the preparation of parasiticides | FRUCHTEL JORG | 2007-07-05 | — | — | US | disclosed |
| EP-1725539-A1 | USE OF PYRIMIDINE COMPOUNDS IN THE PREPARATION OF PARASITICIDES | Novartis AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085211-A1 | USE OF PYRIMIDINE COMPOUNDS IN THE PREPARATION OF PARASITICIDES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| EP-1574502-A1 | Use of pyrimidine compounds in the preparation of parasiticides | Novartis AG (CH) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197902-A1 | Use of Pyrimidine Compounds in the Preparation of Parasiticides | TYMP, TYMS, P2RX1 | MRGPRX1 272/4885MAP4K4 4519/4885F10 211/4885 |
| US-20070155757-A1 | Use of pyrimidine compounds in the preparation of parasiticides | TYMP, TYMS, P2RX1 | MRGPRX1 272/4885MAP4K4 4519/4885F10 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.